Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trial

医学 心肌梗塞 析因分析 心脏病学 内科学 ST段 事后 心室功能 随机对照试验
作者
Denise Tiong,Natalia Pinilla‐Echeverri,David Wood,Roxana Mehran,Robert F. Storey,Laurent J. Feldman,Raúl Moreno,Sunil V. Rao,Warren J. Cantor,Robert C. Welsh,Kevin R. Bainey,Eric A. Cohen,Michael B. Tsang,Matthew Sibbald,Madhu K. Natarajan,Dilani Wijesena,Thenmozhi Mani,Helen Nguyen,John A. Cairns,Shamir R. Mehta
出处
期刊:Eurointervention [European Association of Percutaneous Cardiovascular Interventions]
卷期号:21 (20): e1200-e1210
标识
DOI:10.4244/eij-d-25-00005
摘要

The COMPLETE trial demonstrated a reduction in cardiovascular (CV) death or new myocardial infarction (MI) after complete, rather than culprit-only, revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD). However, it is unknown whether this benefit varies according to baseline left ventricular ejection fraction (LVEF). We aimed to determine the effects of complete versus culprit-only revascularisation according to LVEF. Baseline LVEF was available for 2,214 of 4,041 randomised patients. The effect of both strategies on the first co-primary outcome of CV death or new MI and the second co-primary outcome of CV death, new MI, or ischaemia-driven revascularisation (IDR) was determined within the prespecified LVEF ranges of <45% (N=660) and ≥45% (N=1,554). An analysis of clinical outcomes by LVEF according to thirds was also conducted. Patients with LVEF <45% experienced a significantly higher incidence of the first co-primary outcome compared with those with LVEF ≥45% (4.2%/year vs 2.8%/year; hazard ratio [HR] 1.51, 95% confidence interval [CI]: 1.15-1.98; p=0.003). Compared with a culprit-only strategy, complete revascularisation consistently reduced the first co-primary outcome in patients with LVEF <45% (3.0%/year vs 5.5%/year; HR 0.55, 95% CI: 0.36-0.86) and those with LVEF ≥45% (2.4%/year vs 3.2%/year; HR 0.74, 95% CI: 0.52-1.04; interaction p=0.31). Complete revascularisation also consistently reduced the second co-primary outcome in patients with LVEF <45% (3.5%/year vs 7.3%/year; HR 0.49, 95% CI: 0.33-0.74) and those with LVEF ≥45% (2.7%/year vs 6.3%/year; HR 0.44, 95% CI: 0.33-0.60; interaction p=0.67). Consistent results were observed for both co-primary outcomes when LVEF was further stratified into categories of LVEF ≤35%, 36-49% and ≥50%. Among patients presenting with STEMI and MVD, those with reduced LVEF are at higher risk of ischaemic events than patients with preserved LVEF. There is a consistent benefit of complete revascularisation regardless of baseline LVEF.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6应助执着的诗桃采纳,获得10
刚刚
邱医生完成签到,获得积分20
1秒前
1秒前
xjc关注了科研通微信公众号
3秒前
雪山飞龙发布了新的文献求助10
3秒前
鳗鱼雪巧完成签到,获得积分10
5秒前
SoGoodMan发布了新的文献求助10
5秒前
赘婿应助若初拾光采纳,获得10
5秒前
量子星尘发布了新的文献求助10
6秒前
星辰大海应助User3102675571采纳,获得30
6秒前
从不摸鱼关注了科研通微信公众号
7秒前
科研通AI6应助KanmenRider采纳,获得30
10秒前
10秒前
小郝已读博完成签到 ,获得积分10
10秒前
QZR应助波波采纳,获得20
13秒前
13秒前
Orange应助邓燎原采纳,获得10
14秒前
研友_VZG7GZ应助shuai采纳,获得10
16秒前
科目三应助饶天源采纳,获得10
16秒前
zzz发布了新的文献求助10
17秒前
七柚发布了新的文献求助10
17秒前
18秒前
ML完成签到,获得积分10
18秒前
chen发布了新的文献求助10
20秒前
舒心以蓝完成签到,获得积分10
20秒前
Brave发布了新的文献求助10
21秒前
21秒前
21秒前
曾曾完成签到,获得积分20
22秒前
充电宝应助断桥残雪采纳,获得30
23秒前
李健应助DY采纳,获得20
23秒前
量子星尘发布了新的文献求助10
24秒前
24秒前
从不摸鱼发布了新的文献求助10
24秒前
25秒前
WOW发布了新的文献求助10
26秒前
解语花发布了新的文献求助20
26秒前
孙文杰发布了新的文献求助10
28秒前
UD完成签到,获得积分10
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Acute Mountain Sickness 2000
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Handbook of Milkfat Fractionation Technology and Application, by Kerry E. Kaylegian and Robert C. Lindsay, AOCS Press, 1995 1000
Textbook of Neonatal Resuscitation ® 500
Why Neuroscience Matters in the Classroom 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5049233
求助须知:如何正确求助?哪些是违规求助? 4277322
关于积分的说明 13333357
捐赠科研通 4091953
什么是DOI,文献DOI怎么找? 2239389
邀请新用户注册赠送积分活动 1246254
关于科研通互助平台的介绍 1174828